

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	
Filing Date	February 17, 2004
First Named Inventor	Hector F. DeLuca
Art Unit	1616
Examiner Name	Qazi, Sabiha Naim
Attorney Docket Number	1256-00947

Sheet 1 of 4

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 6,392,071	05-21-2002	DeLuca et al	
		US- 5,945,410	08-31-1999	DeLuca et al	
		US- 5,936,133	08-10-1999	DeLuca et al	
		US- 5,877,168	03-02-1999	Miyamoto et al	
		US- 5,849,726	12-15-1988	Brenner	
		US- 5,846,960	12-08-1998	Labrie	
		US- 5,843,928	12-01-1998	DeLuca et al	
		US- 5,843,927	12-01-1998	DeLuca	
		US- 5,817,648	10-06-1998	Kutner et al	
		US- 5,587,497	12-24-1996	DeLuca et al	
		US- 5,536,713	07-16-1996	DeLuca et al	
		US- 5,246,925	09-21-1993	DeLuca et al	
		US- 5,237,110	08-17-1993	DeLuca et al	
		US- 5,086,191	02-04-1992	DeLuca et al	
		US- 4,666,634	05-19-1987	Miyamoto et al	
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		0184206	12-04-1985	Europe		
		0078704	04-29-1987	Europe		
		0387077	09-03-1990	Europe		
		0474517	11-03-1992	Europe		
		0480572	04-15-1992	Europe		
		0516410	12-02-1992	Europe		

Examiner
Signature

Sabiha Qazi

Date
Considered

9/28/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	
Filing Date	February 17, 2004
First Named Inventor	Hector F. DeLuca
Art Unit	1616
Examiner Name	Qazi, Sabiha Naim
Attorney Docket Number	1256-00947

Sheet 2 of 4**U. S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		WO90/09991	09-07-1990	Calverley et al		
		WO96/01811	01-25-1996	Posner		

Examiner
Signature*Sabiha Qazi*Date
Considered*9/26/04*

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	
Filing Date	February 17, 2004
First Named Inventor	Hector F. DeLuca
Art Unit	1616
Examiner Name	Qazi, Sabiha Naim
Attorney Docket Number	1256-00947

Sheet	3	of	4
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Baggiolini et al, "Stereochemical Total Synthesis of 1a,25-Dihydroxycholecalciferol and 1Beta,25-Dihydroxyerocalciferol", Journal of Organic Chemistry, 51, pp. 3098-3108, 1986.	
		Bouillon et al, "Biological Activity of Dihydroxylated 19-Nor-(Pre)Vitamin D3", Bioactivity of 19-Nor-Pre D, Vol. 8, No. 8, pp. 1009-1015, 1993.	
		Chemical Abstracts, "Chemistry of Synthetic High Polymers", Vol. 110, No. 10, Abstract 110: 82505v, March 6, 1989.	
		Chemical Abstracts, XP-002066055, Vol. 121, No. 21, November 21, 1994.	
		Fujishima et al, "Synthesis and Biological Activity of 2-Methyl-20-EPI Analogues of 1Alpha,25-Dihydroxyvitamin D3," Bioorganic & Medicinal Chemistry Letters, 8, pp. 2145-2148, 1998.	
		Kieguel et al, "Chemical Conversion of Vitamin D3 to its 1,25-Dihydroxy Metabolite", Tetrahedron Letters, Vol. 31, No. 43, pp. 6057-60660, 1991.	
		Konno et al, "A Novel and Practical Route to A-Ring Enyne Synthon for 1Alpha,25-Dihydroxyvitamin D3 Analogs: Synthesis of A-ring Diastereomers of 1Alpha,25-Dihydroxy-Vitamin D3 and 2-Methyl-1,25-Dihydroxyvitamin D3," Bioorganic & Medicinal Chemistry Letters, 8, pp. 151-156, 1998.	
		Okano et al, "Regulatory Activities of 2b-(3-Hydroxypropoxy)-1a,25-Dihydroxyvitamin D3. A Novel Synthetic Vitamin D3 Derivative on Calcium Metabolism", Biochemical and Biophysical Research Communications, Vol. 163, No. 3, pp. 1444-1449, September 29, 1989.	
		Perlman et al, "1a,25-Dihydroxy-19-Nor-Vitamin D3. A Novel Vitamin D-Related Compound with Potential Therapeutic Activity", Tetrahedron Letters, Vol. 31, No. 13, pp. 1823-1824, February 1990.	
		Posner et al, "2-Fluoroalkyl A-Ring Analogs of 1,25-Dihydroxyvitamin D3-Stereocontrolled Total Synthesis via Intramolecular and Intermolecular Diels-Alder Cycloadditions. Preliminary Biological Testing", Journal of Organic Chemistry, 60, pp. 4617-4628, 1995.	

Examiner Signature	<i>Sabiha Qazi</i>	Date Considered	9/26/04
--------------------	--------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number			
		Filing Date	February 17, 2004		
		First Named Inventor	Hector F. DeLuca		
		Art Unit	1616		
		Examiner Name	Qazi, Sabiha Naim		
Sheet	4	of	4	Attorney Docket Number	1256-00947

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Posner et al, "Stereocontrolled Synthesis of a Trihydroxylated A Ring as an Immediate Precursor to 1Alpha,2Alpha,25-Trihydroxyvitamin D3", Journal of Organic Chemistry, 56, pp. 4339-4341, April 15, 1995.	
		Sarandeses et al, "Synthesis of 1Alpha,25-Dihydroxy-19-Norprevitamin D3", tetrahedron Letters, pp. 5445-5448, April 1992.	
SQ		Sicinski et al, "New 1Alpha,25-Dihydroxy-19-Norvitamin D3 Compounds of High Biological Activity: Synthesis and Biological Evaluation of 2-Hydroxymethyl, 2-Methyl, and 2-Methylene Analogues," Journal of Medical Chemistry, 41, pp. 4662-4674, 1998.	
		Slatopolsky et al, "A New Analog of Calcitriol, 19-Nor-1,25-(OH) ₂ D2 Suppresses Parathyroid Hormone Secretion in Uremic Rats in the Absence of Hypercalcemia", American Journal of Kidney Disorders, 26(5), 832-60, 1995.	
		Suhara et al, "Synthesis and Biological Evaluation of Novel 2Alpha-Substituted 1Alpha,25-Dihydroxyvitamin D3 Analogues," Biologianic & Medicinal Chemistry Letters, 10, pp. 1129-1132, March 16, 2000.	

Examiner Signature	Sabiha Qazi	Date Considered	9/26/04
--------------------	-------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.